WCM Investment Management LLC Sells 112,444 Shares of Natera, Inc. (NASDAQ:NTRA)

WCM Investment Management LLC trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 95.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,925 shares of the medical research company's stock after selling 112,444 shares during the quarter. WCM Investment Management LLC's holdings in Natera were worth $745,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Natera by 19.2% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 9,047 shares of the medical research company's stock valued at $827,000 after buying an additional 1,457 shares during the last quarter. Swiss National Bank increased its holdings in shares of Natera by 1.5% in the first quarter. Swiss National Bank now owns 225,400 shares of the medical research company's stock valued at $20,615,000 after buying an additional 3,300 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company's stock valued at $6,810,000 after buying an additional 9,781 shares in the last quarter. Bleakley Financial Group LLC bought a new position in shares of Natera in the first quarter valued at $223,000. Finally, Entropy Technologies LP bought a new position in shares of Natera in the first quarter valued at $788,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 256 shares of the company's stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the sale, the insider now directly owns 111,891 shares in the company, valued at approximately $13,434,752.37. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of the company's stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70. Following the sale, the chief financial officer now directly owns 68,851 shares of the company's stock, valued at approximately $8,706,208.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 256 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now directly owns 111,891 shares in the company, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,464 shares of company stock worth $5,849,977. Corporate insiders own 7.60% of the company's stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Stephens reaffirmed an "overweight" rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. UBS Group lowered their price objective on shares of Natera from $160.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Sanford C. Bernstein lifted their price objective on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Piper Sandler reiterated an "overweight" rating and set a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. Finally, The Goldman Sachs Group lifted their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, October 16th. One analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $135.06.

Natera Stock Up 22.4 %

NASDAQ:NTRA traded up $30.26 during trading hours on Wednesday, reaching $165.38. The company's stock had a trading volume of 2,695,402 shares, compared to its average volume of 1,320,046. The company has a market cap of $20.45 billion, a price-to-earnings ratio of -94.03 and a beta of 1.53. Natera, Inc. has a one year low of $49.97 and a one year high of $167.69. The business's 50-day moving average is $125.09 and its 200-day moving average is $114.52. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.88%. Natera's revenue for the quarter was up 63.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) earnings per share. Equities research analysts predict that Natera, Inc. will post -1.96 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.